These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

378 related items for PubMed ID: 26934441

  • 1. Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation.
    Vigneswaran J, Tan YH, Murgu SD, Won BM, Patton KA, Villaflor VM, Hoffman PC, Hensing T, Hogarth DK, Malik R, MacMahon H, Mueller J, Simon CA, Vigneswaran WT, Wigfield CH, Ferguson MK, Husain AN, Vokes EE, Salgia R.
    Oncotarget; 2016 Apr 05; 7(14):18876-86. PubMed ID: 26934441
    [Abstract] [Full Text] [Related]

  • 2. Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches.
    Drilon A, Wang L, Arcila ME, Balasubramanian S, Greenbowe JR, Ross JS, Stephens P, Lipson D, Miller VA, Kris MG, Ladanyi M, Rizvi NA.
    Clin Cancer Res; 2015 Aug 15; 21(16):3631-9. PubMed ID: 25567908
    [Abstract] [Full Text] [Related]

  • 3. Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative.
    Lim SM, Kim EY, Kim HR, Ali SM, Greenbowe JR, Shim HS, Chang H, Lim S, Paik S, Cho BC.
    Oncotarget; 2016 Apr 26; 7(17):24172-8. PubMed ID: 26992220
    [Abstract] [Full Text] [Related]

  • 4. Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non-Small-Cell Lung Cancer.
    Sacher AG, Dahlberg SE, Heng J, Mach S, Jänne PA, Oxnard GR.
    JAMA Oncol; 2016 Mar 26; 2(3):313-20. PubMed ID: 26720421
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling.
    Schrock AB, Li SD, Frampton GM, Suh J, Braun E, Mehra R, Buck SC, Bufill JA, Peled N, Karim NA, Hsieh KC, Doria M, Knost J, Chen R, Ou SI, Ross JS, Stephens PJ, Fishkin P, Miller VA, Ali SM, Halmos B, Liu JJ.
    J Thorac Oncol; 2017 Jun 26; 12(6):932-942. PubMed ID: 28315738
    [Abstract] [Full Text] [Related]

  • 13. Precision medicine in age-specific non-small-cell-lung-cancer patients: Integrating biomolecular results into clinical practice-A new approach to improve personalized translational research.
    Vavalà T, Monica V, Lo Iacono M, Mele T, Busso S, Righi L, Papotti M, Scagliotti GV, Novello S.
    Lung Cancer; 2017 May 26; 107():84-90. PubMed ID: 27346245
    [Abstract] [Full Text] [Related]

  • 14. Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer.
    Aggarwal C, Thompson JC, Black TA, Katz SI, Fan R, Yee SS, Chien AL, Evans TL, Bauml JM, Alley EW, Ciunci CA, Berman AT, Cohen RB, Lieberman DB, Majmundar KS, Savitch SL, Morrissette JJD, Hwang WT, Elenitoba-Johnson KSJ, Langer CJ, Carpenter EL.
    JAMA Oncol; 2019 Feb 01; 5(2):173-180. PubMed ID: 30325992
    [Abstract] [Full Text] [Related]

  • 15. Variation in targetable genomic alterations in non-small cell lung cancer by genetic ancestry, sex, smoking history, and histology.
    Adib E, Nassar AH, Abou Alaiwi S, Groha S, Akl EW, Sholl LM, Michael KS, Awad MM, Jӓnne PA, Gusev A, Kwiatkowski DJ.
    Genome Med; 2022 Apr 15; 14(1):39. PubMed ID: 35428358
    [Abstract] [Full Text] [Related]

  • 16. Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers.
    Lee B, Lee T, Lee SH, Choi YL, Han J.
    Oncotarget; 2016 Apr 26; 7(17):23874-84. PubMed ID: 26992209
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients - A single centre experience.
    Dall'Olio FG, Conci N, Rossi G, Fiorentino M, De Giglio A, Grilli G, Altimari A, Gruppioni E, Filippini DM, Di Federico A, Nuvola G, Ardizzoni A.
    Lung Cancer; 2020 Nov 26; 149():5-9. PubMed ID: 32932213
    [Abstract] [Full Text] [Related]

  • 19. Distinctive targetable genotypes of younger patients with lung adenocarcinoma: a cBioPortal for cancer genomics data base analysis.
    Hou H, Zhang C, Qi X, Zhou L, Liu D, Lv H, Li T, Sun D, Zhang X.
    Cancer Biol Ther; 2020 Nov 26; 21(1):26-33. PubMed ID: 31594446
    [Abstract] [Full Text] [Related]

  • 20. The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma.
    Qu Y, Che N, Zhao D, Zhang C, Su D, Zhou L, Zhang L, Wang C, Zhang H, Wei L.
    Tumour Biol; 2015 Aug 26; 36(8):6417-24. PubMed ID: 25813151
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.